![if !IE]> <![endif]>
Drugs targeting the interleukin-1 pathway, such as anakinra, canakinumab, and rilonacept, are being investigated for the treat-ment of gout. Although the data are limited, these agents may provide a promising treatment option for acute gout in patients with contraindications to, or who are refractory to, traditional therapies like NSAIDs and/or colchicine. A recent study suggests that canakinumab, a fully human anti-IL-1β monoclonal anti-body, can provide rapid and sustained pain relief at a dose of 150 mg subcutaneously. These medications are also being evalu-ated as therapies for prevention of gout flares while initiating urate-lowering therapy.
Copyright © 2018-2023 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.